Skip to main content


We have a robust program of clinical investigation, with specific interests in the following conditions:

  • Sepsis

We are highly active in outcomes research and research into the delivery of evidence-based care. Specific areas of interest include outcomes of sepsis treatment in rural settings, determinants of outcome in the quarternary medical center, use of electronic early warning systems for sepsis diagnosis, and outcomes in patients with specific conditions, such as hematological malignancies and pulmonary hypertension. We have also worked with members of the School of Engineering at Kansas State University to develop agent based models of innate immunity in sepsis.

  • Pulmonary Hypertension

We have a busy clinical trials program in pulmonary hypertension. Additionally, our division's Director of Research, Navneet Dhillon, PhD, holds three NIH RO1 awards for evaluating basic mechanisms of pulmonary hypertension in patients with HIV infection.

  • Cystic Fibrosis 

Our CF center is a member of the Cystic Fibrosis Foundation's Trials Development Network. We have numerous ongoing therapeutic trials. Additionally, section members lead a national multi-center study on the effect of tele-coaching on medication adherence. We use CF genomics studies to inform our mechanistic basic and translational studies into mechanisms of CF pathophysiology. Our CF section members collaborate with the Department of Pharmacology in the development and testing of nanoparticle deposition of therapeutics.

  • Interstitial Lung Disease

We have a very robust clinical trials program in pulmonary fibrosis.

  • Asthma

The KU Asthma Center focuses on patient-centered outcomes research. Our Asthma Complications in Exercise and Sports (ACES) program focuses on specialized treatment of recreational and competitive athletes of all ages. As an integral component of our ACES program, we run the nation's largest study on the study of Exercise-induced bronchoconstriction (EIB) in competitive athletes at NCAA Division I, II, and III universities.

The Airway & Asthma Research Unit (AATRU) focuses on understanding the origins of asthma and how we can decrease asthma morbidity and mortality using translational methods. We currently have >25 ongoing studies, all of which have opportunities for students, residents, fellows, and junior faculty to perform a focused research in an area of interest.

The AATRU is funded by the National Institutes of Health (NIH), American Lung Association (ALA) and Pharma/Industry in nationally and internationally recognized Clinical Trials and Research. The AATRU focuses on clinical trials that are observational, for precision-medicine, and testing novel therapeutics in conjunction with translational research to understand Asthma using novel imaging techniques as well as biochemical, transcriptional and proteomic approaches.

For additional Information and opportunities go to the AATRU homepage.

  • Hemodynamic monitoring

We are national leaders in the adoption and study of non-invasive hemodynamic monitoring in shock resuscitation.

The division's research is funded by the NIH, the American Lung Association, the American Heart Association, the Cystic Fibrosis Foundation, the CHEST Foundation, and other funding agencies, as well as industry sponsors.

  • Sleep Research

We study sleep disorders in lung disease patients and big data analytics in sleep medicine

Last modified: Feb 05, 2021